Agilent Names Allison Ballmer Senior Vice President of Strategy and Corporate Development

Rhea-AI Summary

Agilent Technologies (NYSE: A) has appointed Allison Ballmer as the new senior vice president of Strategy and Corporate Development. Reporting to CEO Mike McMullen, Ballmer will lead merger-and-acquisition efforts and drive enterprise strategy to foster growth. With nearly 20 years in the biotech sector, including significant experience at Roche, she brings valuable expertise to Agilent's Build-and-Buy growth strategy. Agilent generated $5.34 billion in revenue in fiscal year 2020 and employs over 16,400 people globally.

Positive

• Appointment of Allison Ballmer as senior vice president of Strategy and Corporate Development.
• Ballmer brings nearly 20 years of biotech experience, strengthening executive leadership.
• Her role includes leadership in merger-and-acquisition strategies, enhancing growth prospects.

Negative

• None.

Agilent Technologies Inc.(NYSE: A) is pleased to announce Allison Ballmer has been named the company’s new senior vice president of Strategy and Corporate Development, reporting to Agilent President and CEO Mike McMullen.

Ballmer will lead the corporate development team in identifying, developing, and evaluating merger-and-acquisition plans globally, as well as program management of integrations. She also will lead enterprise strategy while collaborating with Agilent businesses groups to drive critical growth initiatives across the company. Ballmer will serve as a key member of the executive staff and as an adviser to the CEO to help shape the company’s overall strategic direction.

"With nearly 20 years in the biotech industry — the last two being at Agilent — Allison brings a wealth of experience to this role. Her depth of knowledge in global business and marketing will serve Agilent well as we look to continue our Build-and-Buy growth strategy," McMullen said.

Prior to joining Agilent in May 2018 as vice president of Business Development and Strategy for the company’s Diagnostics and Genomics business, Ballmer spent nearly a decade of her career at Switzerland-based Roche, a multinational healthcare company that operates pharmaceutical and diagnostics divisions.

She currently holds the role of lead director of the board of directors at Mission Bio, a California venture-backed company focused on genomics and precision medicine.

Ballmer holds a Bachelor of Science in mechanical engineering from Virginia Polytechnic Institute and State University.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210115005526/en/

FAQ

Who is the new senior vice president of Strategy and Corporate Development at Agilent Technologies?

Allison Ballmer has been appointed as the new senior vice president of Strategy and Corporate Development at Agilent Technologies.

What is Allison Ballmer's experience in the biotech industry?

Allison Ballmer has nearly 20 years of experience in the biotech industry, including significant roles at Roche and Agilent.

What were Agilent Technologies' revenues for fiscal year 2020?

Agilent Technologies generated $5.34 billion in revenue in fiscal year 2020.

What strategic initiatives will Allison Ballmer lead at Agilent Technologies?

Allison Ballmer will lead merger-and-acquisition plans and enterprise strategies to drive growth at Agilent Technologies.